Wall Street Zen Downgrades Mirum Pharmaceuticals (NASDAQ:MIRM) to Hold

Mirum Pharmaceuticals (NASDAQ:MIRM) was downgraded by Wall Street Zen from a “strong-buy” rating to a “hold” rating in a report released on Saturday.

Other equities research analysts also recently issued research reports about the company. Raymond James Financial reissued a “strong-buy” rating and issued a $110.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday, December 11th. Stifel Nicolaus lifted their target price on shares of Mirum Pharmaceuticals from $98.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday. Robert W. Baird boosted their target price on shares of Mirum Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a research report on Monday, December 8th. Evercore reaffirmed an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Thursday. Finally, Morgan Stanley lifted their price objective on shares of Mirum Pharmaceuticals from $95.00 to $123.00 and gave the stock an “overweight” rating in a research note on Friday, January 30th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $114.92.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM stock opened at $92.29 on Friday. The business’s fifty day simple moving average is $93.40 and its 200-day simple moving average is $79.28. The company has a market cap of $5.57 billion, a PE ratio of -192.27 and a beta of 0.52. The company has a current ratio of 2.67, a quick ratio of 2.55 and a debt-to-equity ratio of 0.98. Mirum Pharmaceuticals has a 12-month low of $36.88 and a 12-month high of $109.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.13). Mirum Pharmaceuticals had a negative return on equity of 8.53% and a negative net margin of 4.48%.The business had revenue of $148.93 million during the quarter, compared to analyst estimates of $141.78 million. During the same period in the previous year, the business earned $1.00 EPS. The firm’s revenue for the quarter was up 49.8% compared to the same quarter last year. Analysts expect that Mirum Pharmaceuticals will post -1.43 earnings per share for the current fiscal year.

Insider Activity

In other Mirum Pharmaceuticals news, COO Peter Radovich sold 3,143 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $96.19, for a total transaction of $302,325.17. Following the completion of the transaction, the chief operating officer owned 23,286 shares in the company, valued at approximately $2,239,880.34. This trade represents a 11.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Christopher Peetz sold 9,108 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $103.30, for a total value of $940,856.40. Following the completion of the sale, the chief executive officer owned 160,294 shares in the company, valued at $16,558,370.20. The trade was a 5.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 45,136 shares of company stock valued at $4,352,029 over the last quarter. Insiders own 22.87% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Cullen Frost Bankers Inc. purchased a new stake in Mirum Pharmaceuticals in the 4th quarter worth approximately $30,000. Eurizon Capital SGR S.p.A. purchased a new stake in Mirum Pharmaceuticals during the fourth quarter worth $32,000. CIBC Private Wealth Group LLC purchased a new stake in Mirum Pharmaceuticals during the fourth quarter worth $32,000. MCF Advisors LLC grew its position in Mirum Pharmaceuticals by 76.4% during the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after buying an additional 185 shares during the period. Finally, Quantbot Technologies LP purchased a new position in Mirum Pharmaceuticals in the third quarter valued at $33,000.

Key Stories Impacting Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Q4 revenue beat and strong product growth — Mirum reported ~50% year-over-year revenue growth driven by Livmarli and other drug sales, topping estimates and providing fundamental support for the stock. Mirum’s Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues
• Positive Sentiment: Analyst upgrades/target raises — Stifel raised its price target to $125 (buy) and TD Cowen raised its target to $117 (buy), signaling continued analyst confidence and suggesting meaningful upside from current levels. Analyst Coverage (Benzinga)
• Neutral Sentiment: Analyst consensus roundup — several coverage notes were published (13-analyst roundup) that summarize mixed but generally constructive views; useful for gauging street positioning. 13 Analysts Have This To Say About Mirum Pharmaceuticals
• Neutral Sentiment: Other analyst moves — RBC and Citizens JPM trimmed targets modestly but kept outperform/market outperform ratings, indicating conviction despite small PT adjustments. RBC Commentary (Street Insider)
• Neutral Sentiment: Earnings call and transcripts available — management commentary from the Q4 call provides more detail on commercialization cadence and upcoming catalysts; worth reviewing for guidance tone and commercialization cadence. Q4 2025 Earnings Call Transcript (Fool)
• Negative Sentiment: EPS miss — Mirum reported a GAAP loss of ($0.11) vs. consensus of $0.02, a notable EPS miss that can weigh on sentiment despite the revenue beat. Mirum Reports Q4 Loss, Tops Revenue Estimates (Zacks)
• Negative Sentiment: Guidance mixed — management set FY2026 revenue guidance of $630–$650M vs. a consensus near $646M, leaving limited upside to Street expectations and creating potential downside if execution slips. Press Release / Guidance (Company PDF)
• Negative Sentiment: Short-term pullback coverage — commentary and retail pieces explaining intra-day/short-term weakness (e.g., articles on why MIRM was down) may amplify volatility even as fundamentals improve. Why MIRM Stock Is Down 13.46% (AAII)

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.